ClinicalTrials.gg
CompletedNCT00071006Updated Jun 8, 2012Results posted

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

A Phase 2 interventional study of AG-013736 (Axitinib) in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-08.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Leukemia, Myeloid, Acute by Pfizer — 1 open to participants now, 2 under way, none of them phase 3. Leukemia, Myeloid, Acute · Pfizer.

Enrollment
25th of 26
12 · median 71
Started
2003
the only one that year
Phase 2
10 of 33
none open now
Registered
6th of 33
by date

Among the 33 studies in Leukemia, Myeloid, Acute by Pfizer, this one is the 25th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2003, is one of 10 in phase 2, and was the 6th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

1 of the 33 studies in Leukemia, Myeloid, Acute by Pfizer is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Leukemia, Myeloid, Acute by Pfizer, or all of them as a file.
02

Study summary

The study tests the safety and efficacy of axitinib in patients who have the hematologic disease of Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study tests patients who have poor prognosis before entering the study.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • Myelodysplastic Syndrome
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Poor prognosis AML or MDS
  • Histological confirmation of diagnosis
  • White blood cell count less than or equal to 30,000/mm3
  • Adequate hepatic and renal function documented within 14 days prior to registration
  • (ECOG) performance status of 0, 1, or 2
  • No evidence of preexisting uncontrolled hypertension
  • Not a suitable candidate for chemotherapy
  • No prior systemic chemotherapy treatment for AML or MDS or treatment with an anti-angiogenesis agent

Exclusion criteria

Exclusion Criteria:

  • Patients must not have exclusion criteria.
  • Candidate for chemotherapy
  • Patients with AML M3 (acute promyelocytic leukemia)
  • Conditions that might confound the evaluation of safety or efficacy or increase patient risk.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Single arm study

    Drug: AG-013736 (Axitinib)

Interventions

  • patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response (OR)

    Participants with OR based on a assessment of confirmed complete remission (CR) or partial remission (PR) according to Cheson criteria for Acute myeloid leukemia (AML) and Myelodysplastic syndrome (MDS). CR: those with \> 20% cellularity of bone marrow biopsy, no presence of extramedullary leukemia for AML, \<5 % myeloblast cells for bone marrow with peripheral blood value lasting at least 1 month and 2 months for AML and MDS respectively. PR : those with all criteria for CR except 5-25 % blasts in bone marrow and at least 50% decrease in blast over pretreatment for AML and MDS respectively.

    Time frame: Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 4 weeks up to 35 weeks

Secondary outcomes

  1. Percentage of Participants With Hematologic Improvement (HI)

    HI was described by the number of individual and positively affected cell lines (Erythroid response, Platelet response, Neutrophil response). Improvements must last at least 2 months.

    Time frame: Baseline, Week 2 thereafter every 4 weeks up to 35 weeks and follow up (at least 30 days after last dose)

  2. Duration of Response (DR)

    Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1). DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: First documentation of objective response until objective disease progression or discontinuation from the study due to any cause assessed every 4 weeks up to 35 weeks

  3. Bone Marrow Micro Vessel Density (MVD)

    Bone marrow MVD in tumors is a measure of angiogenesis and a prognostic indicator that correlates with an increased risk of metastasis in various cancers and with overall and relapse free survival in participants with AML or MDS. Bone marrow biopsies and bone marrow clot samples were assessed for MVD (cluster of differentiation 31 \[CD31\] staining).

    Time frame: Day 1, Week 2 thereafter every 4 weeks up to 35 weeks

  4. Vascular Endothelial Growth Factor Receptor 1 (VEGFR-1) and VEFGR Receptor 2 (VEGFR-2) Phosphorylation

    Vascular endothelial growth factor (VEGF) promotes cancer progression by inducing angiogenesis via VEGF receptors, signals directly through receptors VEGFR-1 and VEGFR-2. Change in biomarkers related to VEGFR signal transduction pathways after axitinib treatment was assessed. Mononuclear (MNC) cell VEGF receptor expression and phosphorylation was assessed by in situ western blot analysis. VEGFR-1 and VEGFR-2 evaluations were performed using samples from peripheral blood plasma, bone marrow aspirate, bone marrow (Core) biopsy and bone marrow clot.

    Time frame: Day 1, Week 2 thereafter every 4 weeks up to 35 weeks and follow up (at least 30 days after last dose)

  5. Plasma Vascular Endothelial Growth Factor (VEGF) Concentration

    VEGF promotes cancer progression by inducing angiogenesis via VEGF receptors, signals directly through receptors VEGFR-1 and VEGFR-2. Change in biomarkers related to VEGFR signal transduction pathways after axitinib treatment was assessed. Plasma VEGF concentration evaluations were performed using samples from peripheral blood plasma, bone marrow aspirate, bone marrow (Core) biopsy and bone marrow clot.

    Time frame: Day 1, Week 2 thereafter every 4 weeks up to 35 weeks and follow up (at least 30 days after last dose)

  6. Population Pharmacokinetics of Axitinib (AG-013736)

    Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

    Time frame: Day 1 (pre-dose) and every 4 weeks up to 35 weeks

  7. Overall Survival (OS)

    Time in days from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1). Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.

    Time frame: Baseline to death due to any cause or at least every 3 months after discontinuation of study treatment

07

Results

Posted Mar 19, 2012

Participant flow

Participant flow — Overall Study
MilestoneAxitinib
Started12
Completed0
Not completed12
Withdrew: Lack of efficacy7
Withdrew: Adverse event1
Withdrew: Withdrawal by subject1
Withdrew: Other3

Outcome measures

PrimaryPercentage of Participants With Objective Response (OR)

Participants with OR based on a assessment of confirmed complete remission (CR) or partial remission (PR) according to Cheson criteria for Acute myeloid leukemia (AML) and Myelodysplastic syndrome (MDS). CR: those with \> 20% cellularity of bone marrow biopsy, no presence of extramedullary leukemia for AML, \<5 % myeloblast cells for bone marrow with peripheral blood value lasting at least 1 month and 2 months for AML and MDS respectively. PR : those with all criteria for CR except 5-25 % blasts in bone marrow and at least 50% decrease in blast over pretreatment for AML and MDS respectively.

Time frame:
Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 4 weeks up to 35 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR)
Percentage of participantsAxitinib
Percentage of Participants With Objective Response (OR)0 (0 to 0.265)
SecondaryPercentage of Participants With Hematologic Improvement (HI)

HI was described by the number of individual and positively affected cell lines (Erythroid response, Platelet response, Neutrophil response). Improvements must last at least 2 months.

Time frame:
Baseline, Week 2 thereafter every 4 weeks up to 35 weeks and follow up (at least 30 days after last dose)
Reported as:
Median · Percentage of participants

No measurements were reported for this outcome.

SecondaryDuration of Response (DR)

Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1). DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
First documentation of objective response until objective disease progression or discontinuation from the study due to any cause assessed every 4 weeks up to 35 weeks
Reported as:
Median · Days

No measurements were reported for this outcome.

SecondaryBone Marrow Micro Vessel Density (MVD)

Bone marrow MVD in tumors is a measure of angiogenesis and a prognostic indicator that correlates with an increased risk of metastasis in various cancers and with overall and relapse free survival in participants with AML or MDS. Bone marrow biopsies and bone marrow clot samples were assessed for MVD (cluster of differentiation 31 \[CD31\] staining).

Time frame:
Day 1, Week 2 thereafter every 4 weeks up to 35 weeks
Reported as:
Mean · vessels/square millimeter (mm^2)

No measurements were reported for this outcome.

SecondaryVascular Endothelial Growth Factor Receptor 1 (VEGFR-1) and VEFGR Receptor 2 (VEGFR-2) Phosphorylation

Vascular endothelial growth factor (VEGF) promotes cancer progression by inducing angiogenesis via VEGF receptors, signals directly through receptors VEGFR-1 and VEGFR-2. Change in biomarkers related to VEGFR signal transduction pathways after axitinib treatment was assessed. Mononuclear (MNC) cell VEGF receptor expression and phosphorylation was assessed by in situ western blot analysis. VEGFR-1 and VEGFR-2 evaluations were performed using samples from peripheral blood plasma, bone marrow aspirate, bone marrow (Core) biopsy and bone marrow clot.

Time frame:
Day 1, Week 2 thereafter every 4 weeks up to 35 weeks and follow up (at least 30 days after last dose)
Reported as:
Mean · picograms (pg)/mL

No measurements were reported for this outcome.

SecondaryPlasma Vascular Endothelial Growth Factor (VEGF) Concentration

VEGF promotes cancer progression by inducing angiogenesis via VEGF receptors, signals directly through receptors VEGFR-1 and VEGFR-2. Change in biomarkers related to VEGFR signal transduction pathways after axitinib treatment was assessed. Plasma VEGF concentration evaluations were performed using samples from peripheral blood plasma, bone marrow aspirate, bone marrow (Core) biopsy and bone marrow clot.

Time frame:
Day 1, Week 2 thereafter every 4 weeks up to 35 weeks and follow up (at least 30 days after last dose)
Reported as:
Mean · pg/mL

No measurements were reported for this outcome.

SecondaryPopulation Pharmacokinetics of Axitinib (AG-013736)

Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.

Time frame:
Day 1 (pre-dose) and every 4 weeks up to 35 weeks
Reported as:
Mean · ng/mL

Results for this outcome have not been posted.

SecondaryOverall Survival (OS)

Time in days from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1). Death was determined from adverse event data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.

Time frame:
Baseline to death due to any cause or at least every 3 months after discontinuation of study treatment
Reported as:
Median · Days

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib—9/12 (75%)12/12 (100%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventAxitinib
HypertensionVascular disorders3/12
Febrile neutropeniaBlood and lymphatic system disorders2/12
PainGeneral disorders2/12
PyrexiaGeneral disorders2/12
Blood pressure increasedInvestigations2/12
Back painMusculoskeletal and connective tissue disorders2/12
AnaemiaBlood and lymphatic system disorders1/12
PancytopeniaBlood and lymphatic system disorders1/12
ThrombocytopeniaBlood and lymphatic system disorders1/12
Atrial fibrillationCardiac disorders1/12
Most frequent other events
Showing 10 of 93
Most frequent other events
EventAxitinib
DiarrhoeaGastrointestinal disorders10/12
FatigueGeneral disorders9/12
DysphoniaRespiratory, thoracic and mediastinal disorders9/12
NauseaGastrointestinal disorders6/12
StomatitisGastrointestinal disorders4/12
Mucosal inflammationGeneral disorders4/12
OedemaGeneral disorders4/12
PainGeneral disorders4/12
InfectionInfections and infestations4/12
HypertensionVascular disorders4/12

Baseline characteristics

Age Continuous
Age Continuous(Years)Axitinib
Mean77.42 ± 8.53
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib
Female5
Male7
08

Study locations

1 site
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003, a primary completion of Jul 2004 and a completion of Jul 2004. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 7 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2003
First posted
Oct 13, 2003
Start
Sep 2003
Primary completionActual
Jul 2004
CompletionActual
Jul 2004
Results first posted
Mar 19, 2012
Last update
Jun 8, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00071006
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 13, 2003
Start date
Sep 2003
Primary completion
Jul 2004
Completion
Jul 2004
Results posted
Mar 19, 2012
Last update
Jun 8, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion